{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T19:01:48Z","timestamp":1795201308303,"version":"4.10.3"},"reference-count":26,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Oncology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.seminoncol.2026.152495","type":"journal-article","created":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T06:11:18Z","timestamp":1775455878000},"page":"152495","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Targeting TREM2+tumor-associated macrophages reactivates antitumor immunity and improves anti-PD-1 efficacy in gastric cancer"],"prefix":"10.1016","volume":"53","author":[{"given":"Tianwei","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anwei","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.seminoncol.2026.152495_bib0001","doi-asserted-by":"crossref","DOI":"10.1038\/s41571-023-00747-0","article-title":"Global burden of gastric cancer: epidemiological trends, risk factors, screening and prevention","author":"Thrift","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"issue":"5","key":"10.1016\/j.seminoncol.2026.152495_bib0002","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1097\/CM9.0000000000002108","article-title":"Cancer statistics in China and United States, 2022: profiles, trends, and determinants","volume":"135","author":"Xia","year":"2022","journal-title":"Chin Med J (Engl)"},{"issue":"10251","key":"10.1016\/j.seminoncol.2026.152495_bib0003","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0140-6736(20)31288-5","article-title":"Gastric cancer","volume":"396","author":"Smyth","year":"2020","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.seminoncol.2026.152495_bib0004","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1001\/jamaoncol.2021.0848","article-title":"Efficacy of reduced-intensity chemotherapy with oxaliplatin and capecitabine on quality of life and cancer control among older and frail patients with advanced gastroesophageal cancer: the GO2 phase 3 randomized clinical trial","volume":"7","author":"Hall","year":"2021","journal-title":"JAMA Oncol"},{"issue":"3","key":"10.1016\/j.seminoncol.2026.152495_bib0005","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S1470-2045(08)70035-4","article-title":"S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial","volume":"9","author":"Koizumi","year":"2008","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.seminoncol.2026.152495_bib0006","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1007\/s10120-015-0457-4","article-title":"Randomized multicenter phase III study of a modified docetaxel and cisplatin plus fluorouracil regimen compared with cisplatin and fluorouracil as first-line therapy for advanced or locally recurrent gastric cancer","volume":"19","author":"Wang","year":"2016","journal-title":"Gastric Cancer"},{"issue":"28","key":"10.1016\/j.seminoncol.2026.152495_bib0007","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1200\/JCO.2017.76.6212","article-title":"CheckMate-032 study: efficacy and safety of nivolumab and nivolumab plus ipilimumab in patients with metastatic esophagogastric cancer","volume":"36","author":"Janjigian","year":"2018","journal-title":"J Clin Oncol"},{"issue":"7890","key":"10.1016\/j.seminoncol.2026.152495_bib0008","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/s41586-021-04161-3","article-title":"The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer","volume":"600","author":"Janjigian","year":"2021","journal-title":"Nature"},{"issue":"10294","key":"10.1016\/j.seminoncol.2026.152495_bib0009","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","article-title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial","volume":"398","author":"Janjigian","year":"2021","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.seminoncol.2026.152495_bib0010","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S1470-2045(21)00692-6","volume":"23","author":"Kang","year":"2022","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.seminoncol.2026.152495_bib0011","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1001\/jamaoncol.2020.3370","article-title":"Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: the KEYNOTE-062 phase 3 randomized clinical trial","volume":"6","author":"Shitara","year":"2020","journal-title":"JAMA Oncol"},{"issue":"9","key":"10.1016\/j.seminoncol.2026.152495_bib0012","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1038\/s41588-021-00911-1","article-title":"A single-cell and spatially resolved atlas of human breast cancers","volume":"53","author":"Wu","year":"2021","journal-title":"Nat Genet"},{"key":"10.1016\/j.seminoncol.2026.152495_bib0013","article-title":"Pan-cancer single-cell and spatial-resolved profiling reveals the immunosuppressive role of APOE+ macrophages in immune checkpoint inhibitor therapy","author":"Liu","year":"2024","journal-title":"Adv Sci (Weinh)"},{"issue":"5","key":"10.1016\/j.seminoncol.2026.152495_bib0014","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1111\/jcmm.17191","article-title":"M2-phenotype tumour-associated macrophages upregulate the expression of prognostic predictors MMP14 and INHBA in pancreatic cancer","volume":"26","author":"Liang","year":"2022","journal-title":"J Cell Mol Med"},{"issue":"1","key":"10.1016\/j.seminoncol.2026.152495_bib0015","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1038\/s41467-022-29366-6","article-title":"Single-cell and spatial analysis reveal interaction of FAP(+) fibroblasts and SPP1(+) macrophages in colorectal cancer","volume":"13","author":"Qi","year":"2022","journal-title":"Nat Commun"},{"issue":"6","key":"10.1016\/j.seminoncol.2026.152495_bib0016","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/j.cell.2020.05.003","article-title":"The physiology, pathology, and potential therapeutic applications of the TREM2 signaling pathway","volume":"181","author":"Deczkowska","year":"2020","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.seminoncol.2026.152495_bib0017","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.cell.2020.06.032","article-title":"Coupled scRNA-Seq and intracellular protein activity reveal an immunosuppressive role of TREM2 in cancer","volume":"182","author":"Katzenelenbogen","year":"2020","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.seminoncol.2026.152495_bib0018","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/j.cell.2020.07.013","article-title":"TREM2 modulation remodels the tumor myeloid landscape enhancing Anti-PD-1 immunotherapy","volume":"182","author":"Molgora","year":"2020","journal-title":"Cell"},{"issue":"8","key":"10.1016\/j.seminoncol.2026.152495_bib0019","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1002\/bjs.10546","article-title":"Tryptase expression as a prognostic marker in patients with resected gastric cancer","volume":"104","author":"Lin","year":"2017","journal-title":"Brit J Surg"},{"issue":"7","key":"10.1016\/j.seminoncol.2026.152495_bib0020","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.cell.2022.02.021","article-title":"Tissue-resident FOLR2(+) macrophages associate with CD8(+) T cell infiltration in human breast cancer","volume":"185","author":"Nalio Ramos","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.seminoncol.2026.152495_bib0021","article-title":"Integrated analysis highlights the immunosuppressive role of TREM2(+) macrophages in hepatocellular carcinoma","volume":"13","author":"Zhou","year":"2022","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.seminoncol.2026.152495_bib0022","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.cell.2017.04.014","article-title":"Innate immune landscape in early lung adenocarcinoma by paired single-cell analyses","volume":"169","author":"Lavin","year":"2017","journal-title":"Cell"},{"issue":"12","key":"10.1016\/j.seminoncol.2026.152495_bib0023","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1016\/j.ccell.2021.10.009","article-title":"Single-cell analysis of human non-small cell lung cancer lesions refines tumor classification and patient stratification","volume":"39","author":"Leader","year":"2021","journal-title":"Cancer Cell"},{"issue":"7","key":"10.1016\/j.seminoncol.2026.152495_bib0024","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20201811","article-title":"LILRB4 suppresses immunity in solid tumors and is a potential target for immunotherapy","volume":"218","author":"Sharma","year":"2021","journal-title":"J Exp Med"},{"issue":"1","key":"10.1016\/j.seminoncol.2026.152495_bib0025","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.jhep.2023.02.032","article-title":"TREM2(+) macrophages suppress CD8(+) T-cell infiltration after transarterial chemoembolisation in hepatocellular carcinoma","volume":"79","author":"Tan","year":"2023","journal-title":"J Hepatol"},{"issue":"19","key":"10.1016\/j.seminoncol.2026.152495_bib0026","doi-asserted-by":"crossref","first-page":"3224","DOI":"10.1093\/hmg\/ddaa209","article-title":"Trem2 promotes anti-inflammatory responses in microglia and is suppressed under pro-inflammatory conditions","volume":"29","author":"Liu","year":"2020","journal-title":"Hum Mol Genet"}],"container-title":["Seminars in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775426000424?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775426000424?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T13:12:13Z","timestamp":1780319533000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0093775426000424"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S0093775426000424"],"URL":"https:\/\/doi.org\/10.1016\/j.seminoncol.2026.152495","relation":{},"ISSN":["0093-7754"],"issn-type":[{"value":"0093-7754","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting TREM2+tumor-associated macrophages reactivates antitumor immunity and improves anti-PD-1 efficacy in gastric cancer","name":"articletitle","label":"Article Title"},{"value":"Seminars in Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.seminoncol.2026.152495","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"152495"}}